2025-06-03-Jefferies-生物技术事件记分卡-市场情绪开始好转_9页_469kb

Biotech Event Scorecard Summary - June 2, 2025

Overview

Biotechnology sector experienced mixed performance year-to-date with the XBI index down 10%. The first quarter of 2024 (Q1:24) showed a balanced event quarter with 49% positive events versus 51% negative, as opposed to more negative skew in the last two quarters (around 40% positive).

Sentiment and Performance

• Sentiment is improving due to recent positive data releases (e.g., LLY oral orforglipron T2D, VERA Phase III IgAN, KYMR Phase I STAT6) and sector headwinds being better priced in.
• The market cap shifted positively in Q2 driven by key events, particularly positive Catalysts like LLY data.
• Stock behavior shows improved bounces after negative events (avg +6% return), but continued fading after positive events (avg -4% on Days 2-14), indicating a sector in transition but with persistent profit-taking.

Major Positive Catalysts

• LLY: Oral orforglipron Phase III T2D data returned +14%.
• VERA: Phase III IgAN data delivered +67%.
• KYMR: Phase I STAT6 data moved +46%.
• NVO: Orforglipron Phase III T2D data (readthrough) showed -8%, but obesity data expected later in Q2.
• AMGN: MariTide monthly subQ data anticipated for H2.

Upcoming Catalysts

• Q2 2025 events include LLY obesity data and AMGN MariTide data, likely to influence sentiment further.
• Regulatory milestones with the FDA, including AdCom meetings and the ongoing "listening tour," contributing to sentiment shifts.

Stock Movement Analysis

• Positive events now see a higher bounce rate (67%) compared to prior quarters (30-40%).
• Negative events yield average +6% returns in 14 days, indicating incremental optimism.
• Positive data faders average -4% from Day 2-14, reflecting market caution despite data positivity.

Valuation and Recommendations

• Jefferies assigns ratings based on total return expectations, with "Buy" (15%+ return), "Hold" (10% to -10% return), and "Underperform" (-10% or lower).
• Notable company ratings:
  • AMGN, BHVN, CABA, LLY, NVO, PTC, RYTM, REGN, TVTX, VERA, SVRA, URGN, RCKT, SVRA as BUY.
  • BHVN and NVO ratings tied to specific catalysts.
• Ongoing sector challenges include tariffs, FDA processes, and competition, mitigated by recent positive developments from deals and data.

Concluding Notes

• The report suggests biotech sentiment may have surpassed "peak negativity" as the market digested key impacts.